Europe Generic Drugs Market Analysis and Forecast by Size, Share, Growth, Trends 2031

Q: Which region dominated the Europe Generic Drugs market in 2024?

Germany dominated the market in 2024... Read more

Europe Generic Drugs Market Size and Forecast (2021 - 2031) Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Molecule Type (Antidepressants, Antihistamines, Analgesics, Antibiotics, Antivirals, Diuretics, and Other Molecule Types), Indication (Metabolic Diseases, Cancer, Immunology, Respiratory Disorder, Cardiovascular Disorder, Neurology Disorder, Rare Diseases, and Other Indications), Type (Prescription and OTC Drugs), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Report Date : Oct 2025
Report Code : TIPRE00040934

Category : Life Sciences
Status : Published

Available Report Formats :
No. of Pages : 210

The Europe generic drugs market size is expected to reach US$ 1,14,032.33 million by 2031 from US$ 77,959.65 million in 2024. The market is estimated to record a CAGR of 5.8% from 2025 to 2031.

Executive Summary and Europe Generic Drugs Market Analysis:

The generic drugs market in Europe is poised for strong growth, supported by a well-established healthcare infrastructure, an aging population, and increasing investments in innovative therapies. Europe remains a hub for pharmaceutical and biotech firms, which are actively developing treatments for chronic diseases such as diabetes and cancer. As per WHO, in July 2024, ~64 million adults and ~300,000 children and adolescents had diabetes in the WHO European Region, with one in three cases undiagnosed—creating a clear need for affordable treatment solutions such as generics. By 2045, 1 in 10 Europeans may have diabetes, and Europe already carries the highest burden of type 1 diabetes globally. Cancer is another major health concern, with the WHO reporting over 4.47 million new cases and ~2 million cancer-related deaths in Europe in 2022. As populations age and chronic disease rates rise, the demand for cost-effective alternatives is intensifying.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Europe Generic Drugs Market: Strategic Insights

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst

Europe Generic Drugs Market Segmentation Analysis:

Key segments that contributed to the derivation of the Europe generic drugs market analysis are molecule type, indication, type, and distribution channel.

Based on molecule type, the Europe generic drugs market is segmented into antidepressants, antihistamines, analgesics, antibiotics, antivirals, diuretics, and others. The antibiotics segment held the largest share of the market in 2024.

By indication, the Europe generic drugs market is segmented into metabolic diseases, cancer, immunology, respiratory disorder, cardiovascular disorder, neurology disorder, rare diseases, and others. The cancer segment held the largest share of the market in 2024.

Based on type, the Europe generic drugs market is bifurcated into prescription and OTC drugs. The prescription segment held a larger share of the market in 2024.

By indication, the Europe generic drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2024.

Market Report ScopeEurope Generic Drugs Market Outlook

A significant opportunity in the generic drugs market arises from the digital transformation of healthcare systems and the expansion of public procurement platforms, especially in developing and middle-income countries. As governments and insurers increasingly adopt value-based care and focus on cost containment, there is a growing demand for high-quality, low-cost alternatives to branded medications. This trend provides opportunities for generic manufacturers to integrate into national health supply chains, win bulk tenders, and secure long-term contracts.

Additionally, the rise of e-pharmacies and telemedicine platforms creates new retail channels for generic drugs, particularly in underserved and remote areas. Companies that invest in digital distribution, ensure local regulatory compliance, and engage in public-private partnerships can capitalize on these trends to expand their reach and foster trust in generics as first-line therapies.

Europe Generic Drugs Market Country Insights

Based on country, the Europe generic drugs market comprises the UK, Germany, France, Italy, Spain, and the Rest of Europe. The Rest of Europe held the largest share in 2024.

Norway, Denmark, Sweden, Poland, Ukraine, Romania, Belgium, and the Czech Republic are among the prominent countries in the generic drugs market in the Rest of Europe. The region is experiencing steady growth owing to increasing healthcare demands, cost-containment policies, and expanding chronic disease burdens. These countries benefit from robust healthcare infrastructure, rising investment in biotechnology, and active collaboration between public institutions and private sector players. Amid growing pressure on national healthcare budgets, generic drugs are being adopted as a strategic solution to ensure affordable and sustainable access to medicines. Countries such as the Netherlands and Belgium, which play a central role in the EU's pharmaceutical ecosystem, are increasingly supporting the use of generics and biosimilars to manage treatment costs while maintaining high standards of care. A key demand driver is the rising prevalence of chronic diseases such as cancer and hepatitis. According to Eurostat, over 26% of deaths in several EU countries in 2021 were attributed to cancer-28.2% in Denmark, 27.7% in Ireland, 27.1% in Slovenia, and 26.6% in the Netherlands. These countries also reported a substantial number of new cancer cases: 48,840 in Denmark, 31,242 in Ireland, 14,402 in Slovenia, and 132,319 in the Netherlands. Such statistics highlight the need for cost-effective treatment options, with generic oncology drugs playing an increasingly important role in national health systems. In parallel, local companies are enhancing innovation in low-cost drug development. For example, AstriVax Therapeutics (Belgium), although primarily focused on vaccine development, showcases the region's scientific capabilities. While not directly producing generics, companies such as AstriVax highlight the strong biotech environment that could also be leveraged for generic biologics and biosimilar development in the near future.

Europe Generic Drugs Market Company Profiles

Some of the key players operating in the market include Teva Pharmaceutical Industries Ltd, Viatris Inc, Dr. Reddy's Laboratories Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, AbbVie Inc, AstraZeneca Plc, Sanofi SA, Aurobindo Pharma Ltd, and Glenmark Pharmaceuticals Ltd, among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Europe Generic Drugs Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

Company websites, annual reports, financial statements, broker analyses, and investor presentations.

Industry trade journals and other relevant publications.

Government documents, statistical databases, and market reports.

News articles, press releases, and webcasts specific to companies operating in the market.

Note:

All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

Validate and refine findings from secondary research.

Enhance the expertise and market understanding of the analysis team.

Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers

External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered

This text is related
to segments covered.

Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope

This text is related
to country scope.

Frequently Asked Questions

What is the expected CAGR of the Europe Generic Drugs market?

The market is expected to register a CAGR of 5.8% during 2025–2031.

What would be the estimated value of the Europe Generic Drugs market by 2031?

The Europe Generic Drugs market value is expected to reach US$ 114032.33 million by 2031.

Which are the leading players operating in the Europe Generic Drugs market?

Teva Pharmaceutical Industries Ltd, Viatris Inc, Sandoz Group AG, STADA Arzneimittel AG, and Sun Pharmaceutical Industries Ltd. are among the key players operating in the market.

What are the future trends in the Europe Generic Drugs market?

The Expansion of Biosimilars is likely to emerge as a new growth trend in the market in the coming years.

What are the factors driving the Europe Generic Drugs market growth?

The Rising Chronic Disease Burden and Increasing Demand for Cost-Effective Treatments and Government Policies and Regulatory Support for Generics are among the significant factors fueling the market growth.

Which region dominated the Europe Generic Drugs market in 2024?

Germany dominated the market in 2024.

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research

3.1 Primary Research

3.1.1 Hypothesis formulation:

3.1.2 Macro-economic factor analysis:

3.1.3 Developing base number:

3.1.4 Data Triangulation:

3.1.5 Country level data:

4. Europe Generic Drugs Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Europe:Regulatory Oversight and Key Authorities

4.3 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:

4.4 Average Selling Price, 2024

4.5 Pipeline Analysis:

5. Europe Generic Drugs Market – Key Market Dynamics

5.1 Europe Generic Drugs Market – Key Market Dynamics

5.2 Market Drivers

5.2.1 Patent Expiry and Loss of Market Exclusivity:

5.2.2 Government Policies and Regulatory Support for Generics

5.3 Market Restraints

5.3.1 Intense Price Competition and Thin Profit Margins

5.4 Market Opportunities

5.4.1 Increasing Government Initiatives to promote the use of generic drugs

5.5 Future Trends

5.5.1 Rising Popularity of Biosimilars in the Global Generic Drugs Market

5.6 Impact of Drivers and Restraints:

6. Generic Drugs Market – Europe Analysis

6.1 Europe Generic Drugs Market Revenue (US$ Billion), 2021–2031

6.2 Europe Generic Drugs Market Forecast Analysis

7. Europe Generic Drugs Market Analysis – by Molecule Type

7.1 Antidepressants

7.1.1 Overview

7.1.2 Antidepressants: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

7.2 Antihistamines

7.2.1 Overview

7.2.2 Antihistamines: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

7.3 Analgesics

7.3.1 Overview

7.3.2 Analgesics: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

7.4 Antibiotics

7.4.1 Overview

7.4.2 Antibiotics: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

7.5 Antivirals

7.5.1 Overview

7.5.2 Antivirals: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

7.6 Diuretics

7.6.1 Overview

7.6.2 Diuretics: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

7.7 Others

7.7.1 Overview

7.7.2 Others: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

8. Europe Generic Drugs Market Analysis – by Indication

8.1 Metabolic Diseases

8.1.1 Overview

8.1.2 Metabolic Diseases: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

8.2 Cancer

8.2.1 Overview

8.2.2 Cancer: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

8.3 Immunology

8.3.1 Overview

8.3.2 Immunology: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

8.4 Respiratory Disorder

8.4.1 Overview

8.4.2 Respiratory Disorder: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

8.5 Cardiovascular Disorder

8.5.1 Overview

8.5.2 Cardiovascular Disorder: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

8.6 Neurology Disorder

8.6.1 Overview

8.6.2 Neurology Disorder: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

8.7 Rare Disease

8.7.1 Overview

8.7.2 Rare Disease: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

8.8 Others

8.8.1 Overview

8.8.2 Others: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

9. Europe Generic Drugs Market Analysis – by Type

9.1 Prescription

9.1.1 Overview

9.1.2 Prescription: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

9.2 OTC Drugs

9.2.1 Overview

9.2.2 OTC Drugs: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

10. Europe Generic Drugs Market Analysis – by Distribution Channel

10.1 Hospital Pharmacies

10.1.1 Overview

10.1.2 Hospital Pharmacies: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

10.2 Retail Pharmacies

10.2.1 Overview

10.2.2 Retail Pharmacies: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

10.3 Online Pharmacies

10.3.1 Overview

10.3.2 Online Pharmacies: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

11. Europe Generic Drugs Market – Country Analysis

11.1 Europe

11.1.1 Europe Generic Drugs Market – Revenue and Forecast Analysis – by Country

11.1.1.1 Europe Generic Drugs Market – Revenue and Forecast Analysis – by Country

11.1.1.2 United Kingdom: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

11.1.1.2.1 United Kingdom: Europe Generic Drugs Market Share – by Molecule Type

11.1.1.2.2 United Kingdom: Europe Generic Drugs Market Share – by Indication

11.1.1.2.3 United Kingdom: Europe Generic Drugs Market Share – by Type

11.1.1.2.4 United Kingdom: Europe Generic Drugs Market Share – by Distribution Channel

11.1.1.3 Germany: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

11.1.1.3.1 Germany: Europe Generic Drugs Market Share – by Molecule Type

11.1.1.3.2 Germany: Europe Generic Drugs Market Share – by Indication

11.1.1.3.3 Germany: Europe Generic Drugs Market Share – by Type

11.1.1.3.4 Germany: Europe Generic Drugs Market Share – by Distribution Channel

11.1.1.4 France: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

11.1.1.4.1 France: Europe Generic Drugs Market Share – by Molecule Type

11.1.1.4.2 France: Europe Generic Drugs Market Share – by Indication

11.1.1.4.3 France: Europe Generic Drugs Market Share – by Type

11.1.1.4.4 France: Europe Generic Drugs Market Share – by Distribution Channel

11.1.1.5 Italy: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

11.1.1.5.1 Italy: Europe Generic Drugs Market Share – by Molecule Type

11.1.1.5.2 Italy: Europe Generic Drugs Market Share – by Indication

11.1.1.5.3 Italy: Europe Generic Drugs Market Share – by Type

11.1.1.5.4 Italy: Europe Generic Drugs Market Share – by Distribution Channel

11.1.1.6 Spain: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

11.1.1.6.1 Spain: Europe Generic Drugs Market Share – by Molecule Type

11.1.1.6.2 Spain: Europe Generic Drugs Market Share – by Indication

11.1.1.6.3 Spain: Europe Generic Drugs Market Share – by Type

11.1.1.6.4 Spain: Europe Generic Drugs Market Share – by Distribution Channel

11.1.1.7 Rest of Europe: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

11.1.1.7.1 Rest of Europe: Europe Generic Drugs Market Share – by Molecule Type

11.1.1.7.2 Rest of Europe: Europe Generic Drugs Market Share – by Indication

11.1.1.7.3 Rest of Europe: Europe Generic Drugs Market Share – by Type

11.1.1.7.4 Rest of Europe: Europe Generic Drugs Market Share – by Distribution Channel

12. Industry Landscape

12.1 Overview

12.2 Expansion

12.3 New Product Development/ Launch/ Approvals

12.4 Merger and Acquisition/Partnership

12.5 Other Business Strategies

13. Company Profiles

13.1 Teva Pharmaceutical Industries Ltd

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Viatris Inc

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Dr. Reddy's Laboratories Ltd

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Novartis AG

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Sun Pharmaceutical Industries Ltd

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 AbbVie Inc

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 AstraZeneca Plc

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Sanofi SA

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 Aurobindo Pharma Ltd

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Glenmark Pharmaceuticals Ltd

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 Glossary of Terms

14.2 About The Insight Partners

List of Tables

Table 1. Europe Generic Drugs Market Segmentation

Table 2. Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Table 3. Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Molecule Type

Table 4. Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Indication

Table 5. Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Type

Table 6. Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Distribution Channel

Table 7. Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Country

Table 8. United Kingdom: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type

Table 9. United Kingdom: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication

Table 10. United Kingdom: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type

Table 11. United Kingdom: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel

Table 12. Germany: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type

Table 13. Germany: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication

Table 14. Germany: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type

Table 15. Germany: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel

Table 16. France: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type

Table 17. France: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication

Table 18. France: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type

Table 19. France: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel

Table 20. Italy: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type

Table 21. Italy: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication

Table 22. Italy: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type

Table 23. Italy: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel

Table 24. Spain: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type

Table 25. Spain: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication

Table 26. Spain: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type

Table 27. Spain: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel

Table 28. Rest of Europe: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type

Table 29. Rest of Europe: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication

Table 30. Rest of Europe: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type

Table 31. Rest of Europe: Europe Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel

Table 32. Glossary of Terms, Generic Drugs Market

List of Figures

Figure 1. Europe Generic Drugs Market Segmentation – Country

Figure 2. PEST Analysis

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Europe Generic Drugs Market Revenue (US$ Billion), 2021–2031

Figure 5. Europe Generic Drugs Market Share (%) – by Molecule Type (2024 and 2031)

Figure 6. Antidepressants: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 7. Antihistamines: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 8. Analgesics: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 9. Antibiotics: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 10. Antivirals: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 11. Diuretics: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 12. Others: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 13. Europe Generic Drugs Market Share (%) – by Indication (2024 and 2031)

Figure 14. Metabolic Diseases: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 15. Cancer: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 16. Immunology: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 17. Respiratory Disorder: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 18. Cardiovascular Disorder: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 19. Neurology Disorder: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 20. Rare Disease: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 21. Others: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 22. Europe Generic Drugs Market Share (%) – by Type (2024 and 2031)

Figure 23. Prescription: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 24. OTC Drugs: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 25. Europe Generic Drugs Market Share (%) – by Distribution Channel (2024 and 2031)

Figure 26. Hospital Pharmacies: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 27. Retail Pharmacies: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 28. Online Pharmacies: Europe Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)

Figure 29. Europe Generic Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)

Figure 30. United Kingdom: Europe Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)

Figure 31. Germany: Europe Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)

Figure 32. France: Europe Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)

Figure 33. Italy: Europe Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)

Figure 34. Spain: Europe Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)

Figure 35. Rest of Europe: Europe Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)

Your Key Concerns Addressed - Question & Answer

Can I view a sample of the report before purchasing?

Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

Is analyst support included with the purchase?

Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

What are the next steps once I place an order?

Once your order is successfully placed, you will receive a confirmation email along with your invoice.

• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

Can the report be tailored to suit my specific needs?

We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.

In what format is the report delivered?

The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

How secure is the payment process on your platform?

Our payment process is fully secure and PCI-DSS compliant.

We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.

Do you provide special pricing for buying multiple reports?

Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.

Can I connect with your team to discuss the report before buying?

Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

Will I get a billing invoice upon purchase?

Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.

Is there support available if I can't access my report?

Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
Validates and strengthens in-house secondary research findings
Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

Industry participants: VPs, business development managers, market intelligence managers and national sales managers
Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.